FindTrial
Sign In

PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517047-30-01
Acronym
Pseudovax 1
Enrollment
10
Registered
2025-09-01
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomyxoma Peritonei

Brief summary

Incidence (rate) of IMP-related adverse events, T cell responses against the vaccine peptide in blood samples and skin

Detailed description

Progression-free survival, measured as the number of months from date of first treatment until disease progression or death from any cause

Interventions

DRUGPseudovax
DRUGTislelizumab
DRUGMolgramostim

Sponsors

Oslo University Hospital HF
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Incidence (rate) of IMP-related adverse events, T cell responses against the vaccine peptide in blood samples and skin—

Secondary

MeasureTime frame
Progression-free survival, measured as the number of months from date of first treatment until disease progression or death from any cause—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026